New Jersey Urology (NJU) is the largest single-specialty urology group in the United States. It was formed when Prospect Hill Growth Partners, a leading middle-market private equity firm, formed a practice management services group, Urology Management Associates (UMA), to focus on the urology specialty.
NJU partners with leading urology groups who desire a strategic partner with the capital resources and business expertise to position them for continued success and growth within their markets. NJU removes the burden and increasing complexity of running a medical practice in today’s environment which facilitates the delivery of outstanding care at the lowest possible cost.
OUR LEADERSHIP TEAM
Thomas “Scott” Ciccarelli – Chief Executive Officer
Thomas “Scott” Ciccarelli is an accomplished executive with more than 25 years of experience gained at SRS Health, GE, and Meridian Medical Management with proven operations execution and leadership. His diverse background spans scaling and growing businesses, driving operational excellence, acquisitions, divestitures, integrations and working with Private Equity groups.
Scott leverages a collaborative change management approach and institutes best practices to drive operational excellence and accelerate growth. He strongly believes in transparency, empowerment, collaboration and accountability. With a customer-first mindset, Scott tailors his management approach to address the needs of the stakeholder, whether they are physicians, administrators or front-line employees.
Scott has a B.S. in Engineering from Rutgers University, and a M.B.A. from Weatherhead School of Management at Case Western Reserve University.
Martin M. Goldstein – President of NJU, Senior Vice President of Corporate Development and Acquisitions of UMA
Dr. Goldstein has been a physician leader at NJU for nearly a decade. He has been able to successfully bring physicians together to navigate the changing medical environment. After he had significant success in the formation and sale of a multispecialty ambulatory surgery center, the Metropolitan Surgery Center, he turned his efforts to help create New Jersey Urology. In addition to serving as President of New Jersey Urology, he has been tasked with growing the physician network and adding new ancillary services as Senior Vice President of Corporate Development and Acquisitions.
Dr. Goldstein was awarded a full four-year merit-based scholarship to attend Rutgers University Medical School. He completed his general surgery and urology training at the University of Rochester.
Victor Houtz – Chief Operating Officer
Victor Houtz has served as Chief Operating Officer at New Jersey Urology since 2009. Over the span of ten years, he successfully integrated more than a dozen independent urology practices into New Jersey Urology.
Victor’s prior experience includes public accounting, Fortune 100 corporate services and multiple industry sectors in private companies. He has an MBA from the University of Richmond, and a B.S. from the University of Baltimore.
Chief Financial Officer
OPEN. Visit our careers page to learn more.
Sarah Finnegan – Chief Compliance Officer and General Counsel
Sarah Finnegan joined Urology Management Associates (UMA) in 2018. Prior to joining UMA, Sarah served as the Vice President of Compliance for a national post-acute healthcare provider, and a Senior Vice President of Legal Affairs for another national healthcare provider. She has exclusively served the healthcare sector since 2009, including servicing as outside General Counsel to several prominent long-term care organizations. At UMA, Sarah oversees the Legal and Compliance Department. She received a Bachelor’s Degree in Economics and Political Science from Florida State University, as well as a Juris Doctorate Degree.
Maggie Johnson – Chief Human Resources Officer
Maggie Johnson joined NJU in March 2019. She has 30 years of human resources experience in the healthcare, education, and financial services industries. She brings HR leadership expertise in change management, workforce planning for mergers and acquisitions, turn-around, and high growth situations.
Prior to joining NJU, Maggie was the Chief Human Resources Officer for Sovereign Health System. Maggie’s past experience includes holding the top HR role for a federal and state government contractor and leading provider of substance abuse treatment programs, and healthcare and security management services throughout the US and Bermuda. She also served as the SVP, Human Resources for companies in financial services and education fields.
Maggie earned a law degree (LLB) with honors from the University of London, UK, and holds SPHR and SHRM-SPC designations from HRCI and the Society for Human Resource Management, respectively.
Derek Grimes – Senior Vice President of Clinical Research
Derek Grimes joined NJU/UMA in April 2019. Derek leads NJU’s Clinical Research Organization (CRO) and oversees operational site functions, profit and loss, clinical management and recruitment. He is also responsible for managing and supporting client relationships in the pharmaceutical, biotech and medical device industries.
Prior to joining NJU in April, Mr. Grimes spent nearly twelve years with TKL Research in New Jersey serving as the Vice President of Clinical Operations, where he oversaw the Research Clinics division. He also spent eight years with Columbia and New York Universities managing and developing clinical trials for the universities. Mr. Grimes holds a Bachelor of Science in Health Administration from St. Joseph’s College in Brooklyn, NY.
Adnan T. Savera – Executive Vice President of Pathology and Medical Director
Dr. Savera has served as the Medical Director of NJU Diagnostics since 2017. During this time, NJU Diagnostics has seen tremendous growth and has become a best-in-class lab organization, delivering substantial measurable value to all stakeholders. Dr. Savera is a nationally recognized genitourinary (GU) pathologist with a wealth of experience in academic and commercial arenas. At Henry Ford Hospital, he led the GU pathology, research and consultation services for its ground breaking and globally acclaimed robotic prostatectomy program. He has been recognized by the U.S. Department of Health and Human Services for his contributions to the field of prostate cancer. Dr. Savera previously has also served as Chief Medical Officer and Director of GU Pathology for a national commercial lab that served one of the largest urology client bases in the country.
At NJU, as Executive Vice President of Pathology Dr. Savera is also in charge of laboratory business operations and is responsible for evaluation of ancillary lab tests, implementation of testing protocols and standardization of lab testing utilization throughout the organization.
Glen Gejerman – Senior Vice President of Oncology
A pioneer in new treatments for prostate cancer, Dr. Glen Gejerman serves as Senior Vice President of Oncology at New Jersey Urology. He also serves as Co-Chief of Urologic Oncology and Medical Director of tomotherapy at Hackensack Meridian Health University Medical Center. Image-guided radiation therapy (IGRT), temporary high dose rate (HDR) radiation, tomotherapy and radioactive seed implantation are among the treatment options Dr. Gejerman specializes in. In practice for more than 24 years, he also serves as medical director at multiple radiation oncology departments in New Jersey, enabling him to treat patients statewide.
Honored 12 times as a New Jersey Monthly Top Doctor, Dr. Gejerman is an active author and lecturer, publishing numerous articles and speaking at conferences worldwide.